As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
Nearly half of lymphoma patients treated with Gilead Sciences Inc.’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to presented data.
Danish drugmaker Novo Nordisk is aiming for a big slice of the multibillion-dollar diabetes market with a new pill approved by U.S. authorities that caters for patients with an aversion to needles.
Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission.
A market research report by Clarivate Analytics named “Cortellis Drugs to Watch” identified seven new drugs the company believes will hit sales of $1 billion or more – the so-called “blockbuster” mark – by 2023.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
The European Union approved Roche’s multiple sclerosis medicine Ocrevus, one of the Swiss company’s key new drugs.
Novo Nordisk came closer to winning European approval for the company’s diabetes drug Ozempic, the Danish drugmaker’s largest growth prospect, when a European Medicines Agency experts’ panel issued a positive recommendation.